Copyright
©2014 Baishideng Publishing Group Co.
World J Radiol. Feb 28, 2014; 6(2): 18-25
Published online Feb 28, 2014. doi: 10.4329/wjr.v6.i2.18
Published online Feb 28, 2014. doi: 10.4329/wjr.v6.i2.18
Ref. | Design | No of patients | Tumor size | SABR dose | Toxicity | Outcomes |
Scorsetti et al[15] | Phase II (preliminary report) | 61 (76 tumors) | 1.8-134.3 cm3 (mean 18.6 cm3) | 75 Gy in 3 fractions | No case of RILD. Twenty-six percent had grade 2 transaminase increase (normalised in 3 mo). Grade 2 fatigue in 65% patients, one grade 3 chest wall pain which regressed within 1 year. | 1-yr LC94, 22-mo LC 90.6% |
Goodman et al[16] | Phase I (HCC and liver mets) | 26 (19 liver mets) | 0.8-146.6 mL (median, 32.6 mL) | Dose escalation, 18-30 Gy (1 fr) | No dose-limiting toxicity 4 cases of Grade 2 late toxicity (2 GI, 2 soft tissue/rib) | 1-yr local failure, 3% 2-yr OS, 49% (mets only) |
Ambrosino et al[17] | Prospective cohort | 27 | 20-165 mL (median, 69 mL) | 25-60 Gy (3 fr) | No serious toxicity | Crude LC rate 74% |
Lee et al[18] | Phase I-II | 68 | 1.2-3090 mL (median, 75.9 mL) | Individualized dose, 27.7-60 Gy (6 fr) | No RILD, 10% Grade 3/4 acute toxicity No Grade 3/4 late toxicity | 1-yr LC, 71% Median survival, 17.6 mo |
Rusthoven et al[19] | Phase I-II | 47 | 0.75-97.98 mL (median, 14.93 mL) | Dose escalation, 36-60 Gy (3 fr) | No RILD, Late Grade ¾ < 2% | 1-yr LC, 95% 2-yr LC, 92% Median survival, 20.5 mo |
Høyer et al[10] | Phase II (CRC oligomets) | 64 (44 liver mets) | 1-8.8 cm (median, 3.5 cm) | 45 Gy (3 fr) | One liver failure, two severe late GI Toxicities | 2-yr LC, 79% (by tumor) and 64% (by patient) |
Méndez Romero et al[20] | Phase I-II (HCC and mets) | 25 (17 liver mets) | 1.1-322 mL (median, 22.2 mL) | 30-37.5 Gy (3 fr) | Two Grade 3 liver toxicities | 2-yr LC, 86% 2-yr OS, 62% |
Herfarth et al[21] | Phase I-II | 35 | 1-132 mL (median, 10 mL) | Dose escalation, 14-26 Gy (1 fr) | No significant toxicity reported | 1-yr LC, 71% 18-mo LC, 67% 1-yr OS, 72% |
- Citation: Nair VJ, Pantarotto JR. Treatment of metastatic liver tumors using stereotactic ablative radiotherapy. World J Radiol 2014; 6(2): 18-25
- URL: https://www.wjgnet.com/1949-8470/full/v6/i2/18.htm
- DOI: https://dx.doi.org/10.4329/wjr.v6.i2.18